share_log

FRNT Financial Inc. Announces $3.0M Brokered Financing

FRNT Financial Inc. Announces $3.0M Brokered Financing

FRNT Financial Inc. 宣佈300萬美元的經紀融資
GlobeNewswire ·  04/06 10:43

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

不用於分發給美國新聞通訊社或在美國傳播

TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- FRNT Financial Inc. (TSXV:FRNT) (OTCQB:FRFLF) (FSE:XZ3) (the "Company" or "FRNT") is pleased to announce a brokered private placement offering of up to 5,000,000 units of the Company ("Units") at a price of C$0.60 per Unit (the "Offering Price"), for aggregate gross proceeds of up to C$3,000,000 (the "LIFE Offering"). The Offering is being led by Fort Capital Securities Ltd. (the "Agent") as the sole agent and sole bookrunner on a "best efforts" basis.

多倫多,2024年4月5日(環球通訊社)——FRNT Financial Inc.(多倫多證券交易所股票代碼:FRNT)(OTCQB: FRFLF)(FSE: XZ3)(“公司” 或 “FRNT”)欣然宣佈以每單位0.60加元的價格進行公司高達500萬個單位(“單位”)的經紀私募發行(“發行價格”)”),總收益不超過300萬加元(“人壽發行”)。本次發行由Fort Capital Securities Ltd.(“代理人”)作爲獨家代理人和唯一賬簿管理人在 “盡最大努力” 的基礎上牽頭。

Each Unit will be comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share (each, a "Warrant Share") at an exercise price of C$0.90 for 36 months following the completion of the LIFE Offering, subject to accelerated expiry in the event the volume-weighted average closing price of the Common Shares on the TSX Venture Exchange (the "TSXV") is $1.20 or more for ten (10) consecutive trading days, in which case the Company may accelerate the expiry date of the Warrants to the date that is thirty (30) days following the issuance of a news release by the Company announcing such acceleration.

每個單位將由公司的一股普通股(“普通股”)和一半的普通股購買權證(每份完整認股權證,一份 “認股權證”)組成。每份認股權證的持有人將有權在LIFE發行完成後的36個月內以0.90加元的行使價購買一股普通股(每股 “認股權證”),但如果多倫多證券交易所風險交易所(“TSXV”)普通股的交易量加權平均收盤價在連續十(10)個交易日達到1.20美元或以上,在這種情況下,公司可能會加快到期認股權證的日期至公司發佈新聞稿後的三十(30)天內宣佈這樣的加速。

The Units to be issued under the LIFE Offering will be offered to purchasers pursuant to the Listed Issuer Financing Exemption (the "LIFE Exemption") under Part 5A of National Instrument 45-106 – Prospectus Exemptions, in Alberta, British Columbia, Manitoba, Ontario and Saskatchewan. The Units offered will not be subject to a hold period in accordance with applicable Canadian securities laws.

根據National Instrument 45-106第5A部分的上市發行人融資豁免(“人壽豁免”),在人壽發行下發行的單位將提供給買方— 招股說明書豁免,位於艾伯塔省、不列顛哥倫比亞省、曼尼托巴省、安大略省和薩斯喀徹溫省。根據適用的加拿大證券法,所提供的單位不受持有期限制。

There is an offering document (the "Offering Document") related to the LIFE Offering that can be accessed under the Company's profile on SEDAR+ at and on the Company's website at . Prospective investors of the Units should read the Offering Document before making an investment decision.

有一份與LIFE發行相關的發行文件(“發行文件”)可以在SEDAR+的公司簡介下訪問,網址爲 並在公司的網站上 。在做出投資決定之前,該單位的潛在投資者應閱讀發行文件。

The Company intends to use the net proceeds from the LIFE Offering to continue scaling its business and building out its capital base, and for working capital and general corporate purposes, as more specifically described in the Offering Document. The LIFE Offering is scheduled to close on or about April 30, 2024 or such other date that is within 45 days from April 5, 2024 as the Company and Agent may agree (the "Closing Date"). The Life Offering remains subject to certain conditions customary for transactions of this nature, including, but not limited to, the receipt of all necessary approvals, including the approval of the TSXV.

正如發行文件中更具體地描述的那樣,公司打算將LIFE發行的淨收益用於繼續擴大業務規模和建立資本基礎,並用於營運資金和一般公司用途。LIFE發行計劃於2024年4月30日左右或自2024年4月5日起45天內的其他日期(“截止日期”)結束。人壽發行仍需遵守此類性質交易的某些慣用條件,包括但不限於獲得所有必要的批准,包括多倫多證券交易所的批准。

The securities to be offered pursuant to the LIFE Offering, and sale of the Additional Units, have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

根據LIFE發行發行的證券以及額外單位的銷售,過去和將來都不會根據經修訂的1933年《美國證券法》(“美國證券法”)或任何美國州證券法進行註冊,也不得在美國境內發行或出售,也不得向未經註冊或未經美國註冊要求的適用豁免的美國人發行或出售,或爲其賬戶或利益進行發行或出售。《證券法》和適用的美國州證券法。本新聞稿不應構成在美國出售證券的要約或徵求購買證券的要約,也不得在任何此類要約、招攬或出售非法的司法管轄區出售這些證券。

About FRNT
FRNT is an institutional capital markets and advisory platform focused on digital assets. FRNT, through a technology-forward and compliant operation, aims to bridge the worlds of traditional and web-based finance. Partnering with both financial institutions and crypto native firms, FRNT operates 5 synergistic business lines including deliverable trading services, institutional structured derivative products, merchant banking, advisory and consulting, and principal investments & trading. Co-founded in 2018 by CEO Stéphane Ouellette, FRNT is a global firm headquartered in Toronto, Canada.

關於 FRNT
FRNT是一個專注於數字資產的機構資本市場和諮詢平台。FRNT通過技術前沿和合規的運營,旨在架起傳統金融和網絡金融世界的橋樑。FRNT與金融機構和加密原生公司合作,運營5條協同業務線,包括可交付交易服務、機構結構性衍生品產品、商業銀行、諮詢和諮詢以及本金投資和交易。FRNT是一家全球性公司,總部位於加拿大多倫多,由首席執行官斯蒂芬·歐萊特於2018年共同創立。

FRNT Financial Inc.
Chief Executive Officer
Stéphane Ouellette
investors@frnt.io
833 222-3768

FRNT 金融公司
首席執行官
Ste'phane Ouellette
investors@frnt.io
833 222-3768

Neither the TSXV nor its regulation services provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

FORWARD-LOOKING STATEMENTS

前瞻性陳述

This press release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable law which may include, without limitation, statements relating to the terms and completion of the LIFE Offering, the use of proceeds of the LIFE Offering, the receipt of TSXV approval in respect of the LIFE Offering, acceleration of the expiry date of the Warrants, the technical, financial and business prospects of the Company, its assets and other matters. Generally, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". All forward-looking statements and forward-looking information are based on reasonable assumptions that have been made by the Company as at the date of such information. Forward-looking statements and forward-looking information are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements and forward-looking information, including but not limited to: the general risks associated with the speculative nature of the Company's business, current global financial conditions, uncertainty of additional capital, price volatility, no history of earnings, government regulation in the industries in which the Company operates, political and economic risk, absence of public trading market, arbitrary offering price, dilution to the Company's common shares, dependence on key personnel, currency fluctuations, insurance and uninsured risks, competition, legal proceedings, conflicts of interest and lack of dividends. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements and forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or forward-looking information. The Company does not undertake to update any forward-looking statement or forward-looking information that is included herein, except in accordance with applicable securities laws.

本新聞稿包含適用法律所指的 “前瞻性陳述” 和 “前瞻性信息”,其中可能包括但不限於與人壽發行的條款和完成情況、人壽發行收益的使用、多倫多證券交易所就人壽發行獲得多倫多證券交易所批准、認股權證到期日期的加快、公司的技術、財務和業務前景、其資產和其他事項相關的陳述。通常,前瞻性陳述和前瞻性信息可以通過使用前瞻性術語來識別,例如 “計劃”、“預期” 或 “不期望”、“預期”、“預算”、“估計”、“打算”、“預期” 或 “不預期”、“相信”,或某些行動、事件或結果 “可能”、“可能” 的措辭和短語或陳述的變體, “將”, “可能” 或 “將被採取”, “發生” 或 “實現”.所有前瞻性陳述和前瞻性信息均基於公司在發佈此類信息之日做出的合理假設。前瞻性陳述和前瞻性信息受已知和未知風險、不確定性和其他因素的影響,這些因素可能導致公司的實際業績、活動水平、業績或成就與此類前瞻性陳述和前瞻性信息所表達或暗示的存在重大差異,包括但不限於:與公司業務投機性質相關的一般風險、當前的全球財務狀況、額外資本的不確定性、價格波動、無歷史記錄收益、公司經營所在行業的政府監管、政治和經濟風險、缺乏公開交易市場、任意發行價格、稀釋公司普通股、對關鍵人員的依賴、貨幣波動、保險和未投保風險、競爭、法律訴訟、利益衝突和缺乏股息。儘管公司試圖確定可能導致實際業績與前瞻性陳述和前瞻性信息中包含的業績存在重大差異的重要因素,但可能還有其他因素導致業績與預期、估計或預期不符。無法保證此類信息會被證明是準確的,因爲實際結果和未來事件可能與此類陳述或信息中的預期存在重大差異。因此,讀者不應過分依賴前瞻性陳述或前瞻性信息。除非根據適用的證券法,否則公司不承諾更新此處包含的任何前瞻性陳述或前瞻性信息。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論